382 related articles for article (PubMed ID: 30554335)
1. Immunotherapy Advances in Urothelial Carcinoma.
Jain RK; Snyders T; Nandagopal L; Garje R; Zakharia Y; Gupta S
Curr Treat Options Oncol; 2018 Dec; 19(12):79. PubMed ID: 30554335
[TBL] [Abstract][Full Text] [Related]
2. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
4. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Bednova O; Leyton JV
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
[TBL] [Abstract][Full Text] [Related]
5. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
Minion LE; Tewari KS
Gynecol Oncol; 2018 Mar; 148(3):609-621. PubMed ID: 29666026
[TBL] [Abstract][Full Text] [Related]
6. Role of immunotherapy in bladder cancer.
Rhea LP; Mendez-Marti S; Kim D; Aragon-Ching JB
Cancer Treat Res Commun; 2021; 26():100296. PubMed ID: 33421822
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 testing in urothelial bladder cancer: essentials of clinical practice.
Rouanne M; Radulescu C; Adam J; Allory Y
World J Urol; 2021 May; 39(5):1345-1355. PubMed ID: 33141317
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint inhibitors in BCG-unresponsive nonmuscle invasive bladder cancer: can they help spare the bladder?
El Gharib K; Lilly E; Chebel R
Immunotherapy; 2021 Sep; 13(13):1105-1111. PubMed ID: 34184569
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma.
Fukuokaya W; Kimura T; Yanagisawa T; Kimura S; Tsuzuki S; Koike Y; Iwamoto Y; Enei Y; Tanaka M; Urabe F; Onuma H; Honda M; Miki J; Oyama Y; Abe H; Egawa S
Cancer Immunol Immunother; 2022 Jan; 71(1):229-236. PubMed ID: 34100985
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.
Zichi C; Tucci M; Leone G; Buttigliero C; Vignani F; Pignataro D; Scagliotti GV; Di Maio M
Biomed Res Int; 2017; 2017():5618174. PubMed ID: 28680882
[TBL] [Abstract][Full Text] [Related]
11. Urothelial carcinoma in the era of immune checkpoint inhibitors.
Khalife N; Chahine C; Kordahi M; Felefly T; Kourie HR; Saleh K
Immunotherapy; 2021 Aug; 13(11):953-964. PubMed ID: 34184561
[TBL] [Abstract][Full Text] [Related]
12. Assessment of PD-L1 Status in Urothelial Cancer.
Bahlinger V; Hartmann A; Eckstein M
Methods Mol Biol; 2023; 2684():249-255. PubMed ID: 37410239
[TBL] [Abstract][Full Text] [Related]
13. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.
Grivas P; Agarwal N; Pal S; Kalebasty AR; Sridhar SS; Smith J; Devgan G; Sternberg CN; Bellmunt J
Cancer Treat Rev; 2021 Jun; 97():102187. PubMed ID: 33839438
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for immunotherapy in bladder cancer: a moving target.
Aggen DH; Drake CG
J Immunother Cancer; 2017 Nov; 5(1):94. PubMed ID: 29157296
[TBL] [Abstract][Full Text] [Related]
15. Emerging data on nivolumab for esophageal squamous cell carcinoma.
Hirose T; Yamamoto S; Kato K
Expert Rev Gastroenterol Hepatol; 2021 Aug; 15(8):845-854. PubMed ID: 34251958
[TBL] [Abstract][Full Text] [Related]
16. Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review.
Yang HY; Wu CY; Chen JJ; Lee TH
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256165
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy and Immunotherapy Combinations for Lung Cancer.
Agrawal V; Benjamin KT; Ko EC
Curr Oncol Rep; 2020 Nov; 23(1):4. PubMed ID: 33215306
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma.
Patel A; Bisno DI; Patel HV; Ghodoussipour S; Saraiya B; Mayer T; Singer EA
J Cancer Immunol (Wilmington); 2021; 3(2):115-136. PubMed ID: 34263255
[TBL] [Abstract][Full Text] [Related]
19. Re: Updates in the management and future landscape of urothelial carcinoma.
Sarkis J; Assaf J
J Oncol Pharm Pract; 2021 Mar; 27(2):514-515. PubMed ID: 33349147
[TBL] [Abstract][Full Text] [Related]
20. Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.
Alnajar H; Ravichandran H; Figueiredo Rendeiro A; Ohara K; Al Zoughbi W; Manohar J; Greco N; Sigouros M; Fox J; Muth E; Angiuoli S; Faltas B; Shusterman M; Sternberg CN; Elemento O; Mosquera JM
Cold Spring Harb Mol Case Stud; 2022 Apr; 8(3):. PubMed ID: 35483877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
